Back to Search
Start Over
Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.
- Source :
-
Blood cells, molecules & diseases [Blood Cells Mol Dis] 2021 Sep; Vol. 90, pp. 102588. Date of Electronic Publication: 2021 Jun 15. - Publication Year :
- 2021
-
Abstract
- We present data from our study of plerixafor mobilization (NCT02193191) relevant to the question of whether further dose escalation of plerixafor can address inconsistent adequacy of CD34+ mobilization for gene therapy of sickle cell disease (SCD). We found that, in the same patient, higher plerixafor dosing was associated with higher fold increases in PB CD34+ count, but not necessarily higher absolute CD34+ counts. Variation in pre-apheresis absolute CD34+ counts was related to intra-individual variation in baseline PB CD34+ counts and inter-individual variation in responsiveness to plerixafor. Overall, our results support further studies of continued dose escalation of plerixafor for autologous HPC collection in SCD.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1096-0961
- Volume :
- 90
- Database :
- MEDLINE
- Journal :
- Blood cells, molecules & diseases
- Publication Type :
- Academic Journal
- Accession number :
- 34166998
- Full Text :
- https://doi.org/10.1016/j.bcmd.2021.102588